U.S. BioDefense Wholly Owned Portfolio Company Stem Cell Research Institute, Inc. Successfully Completes Evaluation and Validati

CITY OF INDUSTRY, Calif., Feb. 17  /PRNewswire-FirstCall/ -- U.S. BioDefense (OTC:UBDE) (BULLETIN BOARD: UBDE)  is pleased to announce today that it has successfully completed the evaluation and validation of its human neural crest stem cells as a part of its agreement with  the University of British Columbia.

Director of Research, Dr. Cyndi Chen, Ph.D. stated "This is exciting news for us and the medical community.  The possibilities of developing neural crest stem cell therapies and treatments for a number of degenerative diseases give hopes to those who suffer from these debilitating diseases."

Having passed the initial validation phase, U.S. BioDefense, Inc. is now working toward a full licensing relationship and will begin pre-clinical analysis of how this cell line can be utilized.  Currently, the company is considering investigating the stem cells applications in combating ALS and Parkinson's disease.  U.S. BioDefense, Inc. joins StemCells, Inc. in the fight to find a therapeutic treatment for neurodegenerative diseases in the United States.

On September of 2005, U.S. BioDefense, Inc. received its first stem cell line.  The stem cell line is part of an option to license world patent application WO 03/054202 A1 and US patient application 5,958,767 entitled "Generation of Human Neural Crest Stem Cell Line and Its Utilization in Human Transplantation" and related applications with the University of British Columbia. The line was developed by Dr. Seung Kim and has potential applications in the development of therapeutic treatments for a variety of neurogenerative diseases.

CEO David Chin stated that, "We are pleased to announce to our shareholders the completion of the evaluation phase and look to move forward on completing the negotiation to acquire this amazing technology.  Currently, the existence of immature multi-potent stem cells has been identified in the embryonic and adult human brain and several groups have generated stable, perpetual neural stem cell lines that were utilized for cell replacement or gene transfer therapies in animal models of human neurological disorders.  To this end, we will continue our progress to investigate the potentials of these cells for future clinical prospects."

About Stem Cell Research Institute, Inc.

SCRI is a wholly owned portfolio company of U.S. BioDefense, a strategic biotechnology transfer and holding company, which is focused on accelerating Stem Cell Research.  SCRI has an option to Exclusively License the Neural Crest Stem Cell Line which has been validated by Director of Research Dr. Cyndi Chen in a collaboration agreement with AntiCancer, Inc.  The long term goal is to research, develop, and commercialize novel approaches on utilizing human neural crest stem cell and their potentials in human transplantation to treat neurodegenerative diseases such as Parkinson's and ALS.

Safe Harbor Statement Forward-Looking Statements

Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the U.S. BioDefense's financial performance.  Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements.  In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to the U.S. BioDefense's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism.  Information with respect to important factors that should be considered is contained in the U.S. BioDefense's Annual Report on Form 10-K as filed with the Securities and Exchange Commission.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  The U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

  Contact:
    U.S. BioDefense, Inc.
    David Chin, 626-961-0562
    

DATASOURCE: U.S. BioDefense



CONTACT:  David Chin of U.S. BioDefense, Inc., [phone],

Copyright